The United States Food and Drug Administration has approved two new oral medicines for treating gonorrhoea, a common sexually transmitted infection that has become more difficult to treat as drug resistance spreads around the world. Experts view the decision as a significant step towards providing more patient-friendly treatment options, particularly during a period when doctors have limited reliable alternatives. 

The FDA approved Nuzolvence, also known as zoliflodacin, in the form of water-soluble granules, and Blujepa, also known as gepotidacin, in the form of tablets. Both are intended to treat uncomplicated urogenital gonorrhoea, which is a local infection of the urethra or cervix that has not spread to the rest of the body. Nuzolvence can be used in adults and children aged 12 and up who weigh at least 77 pounds, whereas Blujepa is approved for individuals aged 12 and up who weigh at least 99 pounds, but only when other treatment options are limited owing to safety data limits. 

"These approvals mark an important turning point for treatment options for patients with uncomplicated urogenital gonorrhoea," said Adam Sherwat, M.D., head of the Office of Infectious Diseases in the FDA's Centre for Drug Evaluation and Research. 

Gonorrhoea is caused by the bacterium Neisseria gonorrhoeae. It frequently causes painful urination, peculiar genital discharge, and oedema. If untreated, it can spread to the reproductive organs and cause infertility. For years, treatment was based on a single antibiotic injection, ceftriaxone, while prior combinations failed owing to resistance. 

The latest approvals come amid a global increase in gonococcal antibiotic resistance. "The availability of additional treatment options is of particular importance given the global rise in gonococcal drug resistance," stated Peter Kim, M.D., M.S., director of the FDA's Division of Anti-Infectives. 

Clinical trials demonstrated that both drugs performed nearly as well as the current standard injection-based treatment. In a study of 930 individuals, 91% were cured after receiving a single dosage of Nuzolvence, compared to 96% with standard therapy. Blujepa had a 93% cure rate in a separate study of 628 individuals, which was somewhat higher than the 91% reported with standard treatment. Simply put, most patients were able to clear the illness within a week of taking the medications. 

However, safety continues to be an important priority. Nuzolvence has been associated with adverse effects such as headaches, dizziness, and diarrhoea; animal studies suggest potential hazards during pregnancy. Blujepa has been shown to influence heart rhythm and some brain chemicals, as well as create gastrointestinal discomfort and allergic reactions. The prescription labels clearly state the dangers. 

The FDA gave both medicines special status to speed up their approval because they treat serious infections that have few other treatment options. Entasis Therapeutics authorised Nuzolvence, whereas GSK approved Blujepa. 

For patients, the arrival of effective oral medications may imply easier access, less stigma, and better adherence, even as health officials continue to emphasise prevention and early testing.